Discover how genetically engineered M13 bacteriophages are revolutionizing cancer immunotherapy by targeting dendritic cells and training the immune system to fight cancer.
Discover how bypassing STAT3-mediated inhibition of ID2 enhances dendritic cell function and improves cancer immunotherapy outcomes.